News & Updates

Latest developments in exosome research and company milestones

Genefront Inc Announces $50M Series B Funding Round
Funding
March 15, 2024

Genefront Inc Announces $50M Series B Funding Round

Leading biotech company secures significant funding to accelerate exosome therapeutic development and expand manufacturing capabilities.

Read More
FDA Grants Fast Track Designation for EXO-001 Therapy
Regulatory
February 28, 2024

FDA Grants Fast Track Designation for EXO-001 Therapy

Revolutionary hiPSC-derived exosome treatment receives FDA Fast Track status for cardiovascular disease applications.

Read More
Partnership with Mayo Clinic for Phase II Clinical Trials
Partnership
February 10, 2024

Partnership with Mayo Clinic for Phase II Clinical Trials

Strategic collaboration established for advanced clinical testing of sustained-release exosome therapeutics in neurological disorders.

Read More
Breakthrough in Targeted Brain Delivery Published in Nature
Research
January 22, 2024

Breakthrough in Targeted Brain Delivery Published in Nature

Genefront researchers publish groundbreaking study on blood-brain barrier crossing exosomes with 95% targeting efficiency.

Read More
New GMP Manufacturing Facility Opens in Boston
Manufacturing
December 18, 2023

New GMP Manufacturing Facility Opens in Boston

State-of-the-art 50,000 sq ft facility capable of producing clinical and commercial-scale exosome therapeutics now operational.

Read More
CEO Dr. Sarah Chen Named Biotech Executive of the Year
Awards
November 30, 2023

CEO Dr. Sarah Chen Named Biotech Executive of the Year

Industry recognition for leadership in advancing exosome therapeutics and building successful partnerships across the biotechnology sector.

Read More

Stay Updated

Subscribe to our newsletter for the latest news and developments in exosome therapeutics